Epizyme Inc (EPZM)

15.60
0.55 3.41
NASDAQ : Health Care
Prev Close 16.15
Open 16.10
Day Low/High 15.45 / 16.43
52 Wk Low/High 8.27 / 23.35
Volume 362.80K
Avg Volume 444.90K
Exchange NASDAQ
Shares Outstanding 58.36M
Market Cap 942.49M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Epizyme Announces Date Of First Quarter 2017 Financial Results And Tazemetostat Data Presentations At ASCO

Management to Host Conference Call on May 18, 2017 at 8:30 a.m. ET

Epizyme President Of Research And Chief Scientific Officer, Robert Copeland, Announces Retirement From The Company

Dr. Copeland to Remain a Key Advisor to Epizyme Following Transition

First Week of EPZM April 21st Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the April 21st expiration.

Epizyme is Now Oversold (EPZM)

Epizyme is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting EPZM Put And Call Options For August 18th

Interesting EPZM Put And Call Options For August 18th

Investors in Epizyme Inc. saw new options begin trading this week, for the August 18th expiration.

Commit To Purchase Epizyme At $10, Earn 27.3% Annualized Using Options

Commit To Purchase Epizyme At $10, Earn 27.3% Annualized Using Options

Investors considering a purchase of Epizyme Inc. shares, but cautious about paying the going market price of $11.80/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Epizyme President Of Research And Chief Scientific Officer Named AAAS Fellow

Epizyme President Of Research And Chief Scientific Officer Named AAAS Fellow

Robert A. Copeland, Ph.D., recognized for his insights into epigenetic targets contributing to the development of novel investigational medicines

Epizyme Expands Clinical Programs Through Cooperative Research And Development Agreements With The National Cancer Institute

Epizyme Expands Clinical Programs Through Cooperative Research And Development Agreements With The National Cancer Institute

Studies Will Evaluate Tazemetostat and Pinometostat in Multiple Cancer Indications

Epizyme Establishes Collaboration With Foundation Medicine To Support Tazemetostat Phase 2 Clinical Trial

Epizyme Establishes Collaboration With Foundation Medicine To Support Tazemetostat Phase 2 Clinical Trial

Foundation Medicine Will Identify Individuals with Non-Hodgkin Lymphoma whose Tumors Possess EZH2 Mutations for Potential Enrollment into Epizyme's Phase 2 Clinical Trial

First Week of EPZM May 2017 Options Trading

First Week of EPZM May 2017 Options Trading

Investors in Epizyme Inc. saw new options become available this week, for the May 2017 expiration.

Epizyme Earns $6 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development With First-in-Class PRMT5 Inhibitor

Epizyme Earns $6 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development With First-in-Class PRMT5 Inhibitor

Third Epizyme-discovered product candidate advances into clinical development

Epizyme Doses First Patient In Global Phase 2 Study Evaluating Tazemetostat In Mesothelioma

Epizyme Doses First Patient In Global Phase 2 Study Evaluating Tazemetostat In Mesothelioma

Study Expands Tazemetostat Clinical Program into Patients with Relapsed or Refractory Mesothelioma Characterized by BAP1 Loss-of-Function